Juniper Pharmaceuticals, Inc., a diversified healthcare company focused on women’s health, announced Wednesday that it is exploring strategic alternatives “in order to enhance shareholder value.” The company has engaged Rothschild as its independent financial advisor to assist Juniper and its board in evaluating potential strategic alternatives.
“Over the past year, we have made important investments into our core businesses, Juniper Pharma Services and Crinone, that supported strong double-digit revenue growth and established a strong financial foundation for Juniper,” said Alicia Secor, Juniper’s president and CEO. “Through this process, we are committed to working diligently to support continued growth of the business and to evaluating strategic options that enhance value for our shareholders.”
There can be no assurance that the exploration of strategic alternatives will result in a transaction. Any potential strategic alternative will be evaluated by the board of directors. The company said it does not intend to discuss developments with respect to the evaluation process unless a transaction is approved, or disclosure becomes appropriate.
Juniper’s core businesses include its Crinone (progesterone gel) franchise and Juniper Pharma Services, which provides high-end fee-for-service pharmaceutical development and clinical trials manufacturing to clients. The company is also leveraging its differentiated intravaginal ring technology, which offers the potential to address unmet needs in women’s health.
Juniper Pharmaceuticals is a trademark of Juniper Pharmaceuticals, Inc., in the U.S. and EU.
Crinone is a registered trademark of Merck KGaA, Darmstadt, Germany, outside the U.S. and of Allergan plc in the U.S.
(Source: Juniper Pharmaceuticals, Inc.)